Abstract：Objective To explore and analyze the clinical efficacy and safety of Triptorelin Acetate in the treatment of central precocious puberty in women.Methods A total of 90 girls with central precocious puberty treated in our outpatient clinics and inpatient wards from October 2014 to August 2016 were selected as the study subjects.According to different treatment methods,the patients were evenly divided into two groups,45 cases in each group.In experimental group,patients were treated with Triptorelin Acetate,one year was for a course of treatment.In control group,patients were not provided with any intervention.After one course of treatment,the height,weight,body mass index(BMI)and predicted height before and after treatment were observed,recorded and calculated.The hormone levels such as serum estradiol(E2),follicle stimulating hormone(FSH)and luteinising hormone(LH)before and after therapy were determined in order to evaluate the therapeutic efficacy.ResultsAfter one course of treatment,the height,weight,predicted height,bone age of the two groups were significantly higher than before treatment,the differences were statistically significant(P＜0.05).The the height,weight and predicted height in the experimental group were much higher than those of the control group,while the bone age of the experimental group were significantly lower compared with those in the control group,the differences were statistically significant(P＜0.05).The serum levels of E2,FSH and LH after therapy in the two groups were significantly lower than those before treatment with statistical significance (P＜0.05).The levels of E2,FSH and LH in the experimental group were significantly lower than in the control group,the differences were statistically significant(P＜0.05).The incidence of adverse reactions in the experimental group was significantly lower than that in the control group,and the difference was statistically significant(P＜0.05).Conclusion The effect of Triptorelin Acetate in the treatment of female central precocious puberty is good and worthy of clinical promotion.
魏苗苗. 醋酸曲普瑞林治疗女性中枢性性早熟的效果与安全性探讨[J]. 中国当代医药, 2018, 25(11): 136-138.
WEI Miao-miao. Therapeutic effect and safety of Triptorelin Acetate in the treatment of central precocious puberty in women. 中国当代医药, 2018, 25(11): 136-138.
Ahmet A，Catll Gonül，Ayhan A，et al.Effect of gonadotropinreleasing hormone agonist therapy on body mass index and growth in girls with idiopathic central precocious puberty[J].Indian J Endocrinol Metab，2015，19（2）：267-271.
Giabicani E，Lemaire P，Brauner R.Models for predicting the adultheight and age at first menstruation of girls with idiopathic centralprecociouspuberty[J].PLoS One，2015，10（3）：e0120588.
京公网安备 11010502046607号